MiMedx Group (MDXG) to Post Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is expected to issue its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect MiMedx Group to announce earnings of ($0.0340) per share and revenue of $63.46 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $58.99 million during the quarter, compared to the consensus estimate of $65.80 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%. On average, analysts expect MiMedx Group to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $4.32 on Wednesday. The company has a current ratio of 5.39, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $643.45 million, a P/E ratio of 21.60 and a beta of 1.45. The business has a fifty day simple moving average of $3.83 and a two-hundred day simple moving average of $4.35. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.99.

Hedge Funds Weigh In On MiMedx Group

Hedge funds have recently bought and sold shares of the business. Kemnay Advisory Services Inc. bought a new position in MiMedx Group during the 4th quarter valued at about $48,000. Headlands Technologies LLC purchased a new position in shares of MiMedx Group during the second quarter valued at approximately $72,000. Jain Global LLC purchased a new position in shares of MiMedx Group during the fourth quarter valued at approximately $73,000. Virtu Financial LLC bought a new position in MiMedx Group during the fourth quarter valued at approximately $78,000. Finally, Osaic Holdings Inc. lifted its position in MiMedx Group by 57.2% during the second quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock valued at $79,000 after purchasing an additional 4,708 shares during the period. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on MDXG shares. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Wall Street Zen lowered shares of MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Craig Hallum decreased their target price on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Citizens Jmp lowered their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.